Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial

ABSTRACT: Introduction: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo. Methods: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. Results: We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non-carriers, 30 to 53 years of age. Carriers were significantly younger than non-carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. Discussion: Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non-carriers. Their demographic characteristics are representative of the local population. Keywords: Alzheimer's Prevention Initiative; Alzheimer's disease; autosomal-dominant Alzheimer's disease; baseline data; clinical trial; crenezumab; preclinical; preclinical Alzheimer's disease; prevention.

• Autores: Tobón Quintero, Carlos Andrés; Lopera Restrepo, Francisco Javier; Ríos Romenets, Silvia; Sink, Kaycee M.; Hu, Nan; Lian, Qinshu; Guthrie, Heather; Smith, Jillian; Cho, William; Mackey, Howard; Langbaum, Jessica B.; Thomas, Ronald G.; Giraldo Chica, Margarita María; Acosta Baena, Natalia; Muñoz Zapata, Claudia Cecilia; Ospina Lopera, Paula Andrea; Tirado Pérez, Victoria Claudia; Henao Arboleda, Eliana; Bocanegra García, Orfa Yamile; Chen, Kewei; Su, Yi; Goradia, Dhruman; Thiyyagura, Pradeep; VanGilder, Paul S.; Luo, Ji; Ghisays, Valentina; Lee, Wendy; Malek Ahmadi, Michael H.; Protas, Hillary D.; Chen, Yinghua; Quiroz Gaviria, Yakeel Tatiana; Reiman, Eric M.; Tariot, Pierre N.
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2020
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/43065
• Acceso en línea: https://hdl.handle.net/10495/43065
• Palabra clave: Alzheimer Disease; Enfermedad de Alzheimer; Antibodies, Monoclonal, Humanized; Anticuerpos Monoclonales Humanizados; Cognition; Cognición; Mutation; Mutación; Neuropsychological Tests; Pruebas Neuropsicológicas; Presenilin-1; Presenilina-1; https://id.nlm.nih.gov/mesh/D000544; https://id.nlm.nih.gov/mesh/D061067; https://id.nlm.nih.gov/mesh/D003071; https://id.nlm.nih.gov/mesh/D009154; https://id.nlm.nih.gov/mesh/D009483; https://id.nlm.nih.gov/mesh/D053764
• Rights: openAccess
• License: https://creativecommons.org/licenses/by-nc/4.0/